SGLT2 inhibitors - such as dapagliflozin, canagliflozin, and empagliflozin - have demonstrated consistent renal and cardiovascular benefits in patients with type 2 diabetes, as evidenced by the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), and Study of Heart and Kidney Protection with Empagliflozin (EMPA-KIDNEY) trials, as well as a comprehensive meta-analysis of cardiovascular outcome studies [8,19-21]. This evidence concerns the gene SLC5A2 and chronic kidney disease.